Clinical trial · Observational
Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens
The Impact of Nursing and Pharmacy Care Between Xeloda® and 5-Fluoruracil Regimens in the Management of Colorectal Cancer (CRC) in Hong Kong
NCT01801085CI-TRIAL-00025760terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow recruitment pace
Summary
Brief summary (as posted)
This is a prospective time-and-motion study to document and compare the time used in preparation, dispensing and administration for capecitabine/oxaliplatin (XELOX) versus IV 5-FU/leucovorin/oxaliplatin (FOLFOX4) regimens in colorectal cancer (CRC) patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- FOLFOX4
- description
- Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
- label
- XELOX
- description
- Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
Primary outcomes (1)
- measure
- Composite preparation, dispensing and administration time
- timeFrame
- Up to 6 months after the initiation of chemotherapy
- description
- Composite time is measured via real-time recording. Total length of the said time points are to be recorded using a stop-watch and the sum is tabulated in the end.
Secondary outcomes (1)
- measure
- Capital item utilization (hospital bed and infusion pump)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 or above * Diagnosed with CRC and prescribed with either XELOX for FOLFOX4 chemotherapy treatment Exclusion Criteria: * Patients less than 18 years of age * Persons related unequally to investigators * Patients who are mentally/cognitively disabled * Patients who refuse to give consent to participate
References
Publications (0)
Data not yet available
No reference posted for this study.